Compare abrdn Income Credit Strategies Fund (ACP) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Bristol-Myers Squibb Co — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Bristol-Myers Squibb Co trades at $57.92 (market cap $118.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 180.4× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | BMY | |
|---|---|---|
Market Cap | $656.21M | $118.38B |
Sector | Financials | Health |
52-Week High | $5.98 | $62.37 |
52-Week Low | $5.01 | $42.60 |
Dividend Yield | 17.78% | 4.35% |
Enterprise Value | — | $154.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Bristol Myers Squibb (BMY) trades at $57.97, down 0.28% today, with a bullish technical signal and consistent earnings beats. The company maintains strong profitability with a 15.01% net income margin and a 4.3% dividend yield. Recent news highlights its growth portfolio now comprising over 54% of revenues, though patent cliff concerns persist. Cash flow from operations remains robust at $14.16B for 2025, supporting dividend sustainability.
BMY offers value with a P/E of 15.88 below industry averages, but faces significant patent expiration risks that could pressure future revenues. Analyst consensus is mixed with a $64.33 price target suggesting 11% upside. The stock is a cash flow machine with upside potential if new drug pipelines deliver, though investors must weigh growth execution against legacy portfolio declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
